Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA.

BMC Cancer · 2025 · PMC12641966 · PMID 41286758

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

On the other hand, patients with CCND1 or FGF19 amplification showed a trend towards higher recurrence risk in our cohort.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.